Biotech Values

[genisi]

Since the Teva settlement in 2005, several other generic manufacturers have filed paragraph IV against Wyeth's Effexor XR and WYE has settled with six of them. However, there are a few more that didn't settle yet and can still launch a generic in the US in Jan 2011, as soon as Teva's exclusivity expires. So, not sure Teva will be alone for eleven months, but it's possible.

On knockoff of Effexor XR: there's the potential for Sun to launch a non-AB rated version but you're right that the UCB/Osmotica version has had limited success in the US.